THAR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.37%

Insider Buying (Last 12 Months): $49,462.50

Insider Selling (Last 12 Months): $0.00

Tharimmune Insider Trading History Chart

Tharimmune Share Price & Price History

^$2.11

▼ -0.07 (-3.21%)

As of 11/14/2024 11:45 AM ET

Days: 30 | 90 | 365

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Claim your FREE 2024 Gold Guide

Tharimmune Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/13/2024	Sireesh Appajosyula	COO	Buy	5,000	$2.02	$10,100.00	10,758
10/8/2024	Randy Milby	CEO	Buy	2,500	$2.09	$5,225.00	12,934
10/8/2024	Sireesh Appajosyula	COO	Buy	5,000	$1.93	$9,650.00	16,364
12/15/2023	Randy Milby	CEO	Buy	1,933	$7.50	$14,497.50	10,434
11/30/2023	Randy Milby	CEO	Buy	666	$15.00	$9,990.00	8,501

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Tharimmune (NASDAQ:THAR)

1.16% of Tharimmune stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Tharimmune Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company	Details
11/6/2024	Curi RMB Capital LLC	23,620	$59K	0.0%	N/A	2.056%

Data available starting January 2016

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Today's Range

Now: $2.11

$2.11

$2.25

50 Day Range

MA: $2.47

$1.92

$3.43

52 Week Range

Now: $2.11

$1.84

$79.65

Volume

43,727 shs

Average Volume

330,798 shs

Market Capitalization

$3.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Who are the company insiders with the largest holdings of Tharimmune?: Tharimmune's top insider shareholders include:
Sireesh Appajosyula (COO)
Randy Milby (CEO)
Learn More about top insider investors at Tharimmune.
Who are the major institutional investors of Tharimmune?: Tharimmune's top institutional shareholders include:
Curi RMB Capital LLC — 2.06%
Learn More about top institutional investors of Tharimmune stock.
Which major investors are buying Tharimmune stock?: During the last quarter, THAR stock was bought by institutional investors including:
Curi RMB Capital LLC
Within the last year, these company insiders have bought Tharimmune stock:
Sireesh Appajosyula (COO)
Randy Milby (CEO)
Learn More investors buying Tharimmune stock.